Kaposi Sarcoma - Pipeline Review, H1 2020

March 2020 | 294 pages | ID: K23FF739D03EN
Global Markets Direct

Abstracts

Kaposi Sarcoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2020, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 4, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Kaposi Sarcoma - Overview
Kaposi Sarcoma - Therapeutics Development
Kaposi Sarcoma - Therapeutics Assessment
Kaposi Sarcoma - Companies Involved in Therapeutics Development
Kaposi Sarcoma - Drug Profiles
Kaposi Sarcoma - Dormant Projects
Kaposi Sarcoma - Discontinued Products
Kaposi Sarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Kaposi Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Kaposi Sarcoma - Pipeline by Aphios Corp, H1 2020
Kaposi Sarcoma - Pipeline by Bristol-Myers Squibb Co, H1 2020
Kaposi Sarcoma - Pipeline by Cannabis Science Inc, H1 2020
Kaposi Sarcoma - Pipeline by Cello Therapeutics Inc, H1 2020
Kaposi Sarcoma - Pipeline by Genexine Inc, H1 2020
Kaposi Sarcoma - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2020
Kaposi Sarcoma - Pipeline by VasGene Therapeutics Inc, H1 2020
Kaposi Sarcoma - Dormant Projects, H1 2020
Kaposi Sarcoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Kaposi Sarcoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Kaposi Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aphios Corp
Bristol-Myers Squibb Co
Cannabis Science Inc
Cello Therapeutics Inc
Genexine Inc
LATITUDE Pharmaceuticals Inc
LipoSeuticals Inc
Merck & Co Inc
Nammi Therapeutics Inc
Ono Pharmaceutical Co Ltd
Tumorend LLC
VasGene Therapeutics Inc